Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Functionalized gold nanoparticles for drug delivery.

Han G, Ghosh P, Rotello VM.

Nanomedicine (Lond). 2007 Feb;2(1):113-23. Review.

PMID:
17716197
2.

Ocular drug delivery: nanomedicine applications.

Vandervoort J, Ludwig A.

Nanomedicine (Lond). 2007 Feb;2(1):11-21. Review.

PMID:
17716187
3.

The forthcoming applications of gold nanoparticles in drug and gene delivery systems.

Pissuwan D, Niidome T, Cortie MB.

J Control Release. 2011 Jan 5;149(1):65-71. doi: 10.1016/j.jconrel.2009.12.006. Review.

PMID:
20004222
4.
5.

Integration column: biofunctional polymeric nanoparticles for spatio-temporal control of drug delivery and biomedical applications.

Rothenfluh DA, Hubbell JA.

Integr Biol (Camb). 2009 Jul;1(7):446-51. doi: 10.1039/b907627c. Review.

PMID:
20023754
6.

Stimuli-responsive polymeric nanoparticles for nanomedicine.

Crucho CI.

ChemMedChem. 2015 Jan;10(1):24-38. doi: 10.1002/cmdc.201402290. Review.

PMID:
25319803
7.

Production and characterization of gamma-polyglutamic acid nanoparticles for controlled anticancer drug release.

Manocha B, Margaritis A.

Crit Rev Biotechnol. 2008;28(2):83-99. doi: 10.1080/07388550802107483 . Review.

PMID:
18568849
8.

Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.

Son SJ, Bai X, Lee SB.

Drug Discov Today. 2007 Aug;12(15-16):650-6. Review.

PMID:
17706547
9.

Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 2: Imaging, diagnostic, and therapeutic applications.

Son SJ, Bai X, Lee SB.

Drug Discov Today. 2007 Aug;12(15-16):657-63. Review.

PMID:
17706548
10.

Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery.

Delehanty JB, Boeneman K, Bradburne CE, Robertson K, Bongard JE, Medintz IL.

Ther Deliv. 2010 Sep;1(3):411-33. Review.

PMID:
22816144
11.

Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery.

Yoo JW, Doshi N, Mitragotri S.

Adv Drug Deliv Rev. 2011 Nov;63(14-15):1247-56. doi: 10.1016/j.addr.2011.05.004. Review.

PMID:
21605607
12.

Particle shape effects in vitro and in vivo.

Harris BJ, Dalhaimer P.

Front Biosci (Schol Ed). 2012 Jun 1;4:1344-53. Review.

PMID:
22652876
13.

Characterization of nanoparticles for therapeutics.

Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE.

Nanomedicine (Lond). 2007 Dec;2(6):789-803. Review.

PMID:
18095846
14.

[Progress of researches on drug-loaded nanoparticles].

Zhao J, Sheng Y, Shan X, Zhang X, Yuan Y, Liu C.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008 Feb;25(1):220-3. Review. Chinese.

PMID:
18435295
15.

Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.

Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow KC, Wickline SA.

Nanomedicine (Lond). 2006 Oct;1(3):321-9. Review.

PMID:
17716162
16.

Inorganic nanoparticles in cancer therapy.

Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P.

Pharm Res. 2011 Feb;28(2):237-59. doi: 10.1007/s11095-010-0318-0. Review.

17.

Use of degradable and nondegradable nanomaterials for controlled release.

Wan WK, Yang L, Padavan DT.

Nanomedicine (Lond). 2007 Aug;2(4):483-509. Review.

PMID:
17716133
18.

Micro- and nanoparticles--medical applications.

Jătariu A, Peptu C, Popa M, Indrei A.

Rev Med Chir Soc Med Nat Iasi. 2009 Oct-Dec;113(4):1160-9. Review.

PMID:
20191893
19.

Liposomal drug delivery systems: from concept to clinical applications.

Allen TM, Cullis PR.

Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. doi: 10.1016/j.addr.2012.09.037. Review.

PMID:
23036225
20.

Halloysite clay nanotubes for controlled release of protective agents.

Lvov YM, Shchukin DG, Möhwald H, Price RR.

ACS Nano. 2008 May;2(5):814-20. doi: 10.1021/nn800259q. Review.

PMID:
19206476
Items per page

Supplemental Content

Support Center